Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports.
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
AlphaQuest LLC Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...
Business Insider1mon
Mirum Pharmaceuticals sees FY25 product sales of $420M-$435M vs. $336.4M in FY24
16:06 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $420M-$435M vs. $336.4M in FY24 See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...